VMP 35911211000001106

Search dm+d | This VMP cannot be matched against our prescribing data.

Name Bevacizumab 400mg/16ml solution for infusion vials
BNF code 0801050APAAABAB
Virtual Therapeutic Moiety Bevacizumab
Date identifier became valid 19 Oct 2018
Previous product identifier 409410005
Basis of preferred name rINN - Recommended International Non-proprietary
Date of name applicability 14 Jan 2009
Previous name Bevacizumab 400mg/16ml solution for injection vials
Basis of previous name rINN - Recommended International Non-proprietary
Reason for name change Other
Prescribing status Caution - AMP level prescribing advised
Sugar free
Gluten free
Preservative free
CFC free
Dose form Discrete
Unit dose form size 16.000
Unit dose form units ml
Unit dose unit of measure vial
Virtual Product Ingredient
Ingredient Bevacizumab
Basis of pharmaceutical strength Based on Ingredient Substance
Strength value numerator 25.000
Strength value numerator unit mg
Strength value denominator 1.000
Strength value denominator unit ml
Ontology Drug Form & Route
Form & Route solutioninfusion.intravenous
Dose Form
Formulation Solution for infusion
Drug Route
Route Intravenous
Controlled Drug Prescribing Information
Controlled Drug category No Controlled Drug Status
Actual Medicinal Products
Alymsys 400mg/16ml concentrate for solution for infusion vials (Zentiva Pharma UK Ltd)
Avastin 400mg/16ml solution for infusion vials (Roche Products Ltd)
Aybintio 400mg/16ml solution for infusion vials (Organon Pharma (UK) Ltd)
Oyavas 400mg/16ml concentrate for solution for infusion vials (Thornton & Ross Ltd)
Vegzelma 400mg/16ml concentrate for solution for infusion vials (Celltrion Healthcare UK Ltd)
Versavo 400mg/16ml concentrate for solution for infusion vials (Dr Reddy's Laboratories (UK) Ltd)
Zirabev 400mg/16ml solution for infusion vials (Pfizer Ltd)
Virtual Medicinal Product Packs
Bevacizumab 400mg/16ml solution for infusion vials 1 vial

dm+d data retrieved from TRUD: release NHSBSA_4.4.0_20240429000001, imported on 29th April 2024 at 05:07:25.

Feedback